

Ref. No: 2672
Date: 3rd July
Subject: Diffuse Large B Cell Lymphoma (DLBCL)

REQUEST

Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)?

Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months?

Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments:

- R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)
- R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)
- R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)
- R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)
- (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Axicabtagene ciloleucel
- Tisagenlecleucel
- Epcoritamab
- Loncastuximab tesirine
- Glofitamab
- Any other SACT
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Glofitamab + GemOx (gemcitabine and oxaliplatin)

Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL):

- Axicabtagene ciloleucel (Yescarta)
- Tisagenlecleucel
- Pola-BR (polatuzumab vedotin with rituximab and bendamustine)
- R-GemOX (rituximab, gemcitabine and oxaliplatin)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Glofitamab + GemOx (gemcitabine and oxaliplatin)
- Any other treatments

Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (DLBCL)?

Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- CAR-T Therapy (E.g. Axicabtagene ciloleucel)
- Stem cell transplant or bone marrow transplant (autologous or allogeneic)
- Any other treatment

RESPONSE

Q1

In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL) (ICD 10 – C83.3). 01/01/2026 – 30/06/2026

Southport & Ormskirk	Whiston & St Helens
8	12

Q1a

Of these patients, how many commenced treatment at your trust within the last 6 months? (ICD 10 – C83.3) 01/01/2026 – 30/06/2026

Southport & Ormskirk	Whiston & St Helens
<5	9

Q2

Protocol	Southport & Ormskirk	Whiston & St Helens
R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and	6	21

prednisolone)		
R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone)	0	0
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	<5	0
Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone)	0	<5
R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate)	0	0
R-IVAC (rituximab, ifosfamide, etoposide and cytarabine)	0	0
R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone)	0	0
(DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab)	0	0
R-GemOX (rituximab, gemcitabine and oxaliplatin)	0	0
Axicabtagene ciloleucel	0	0
Tisagenlecleucel	0	0
Epcoritamab	0	0
Loncastuximab tesirine	<5	0
Glofitamab	0	0
Any other SACT	0	<5
Glofitamab + GemOx (gemcitabine and oxaliplatin)	0	<5

Q3

Protocol	Southport & Ormskirk	Whiston & St Helens
Axicabtagene ciloleucel (Yescarta)	0	0
Tisagenlecleucel	0	0
Pola-BR (polatuzumab vedotin with rituximab and bendamustine)	0	0
R-GemOX (rituximab, gemcitabine and oxaliplatin)	0	0
Glofitamab + GemOx (gemcitabine and oxaliplatin)	0	<5
Any other treatments	0	<5

Q4

In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL) (ICD 10 – C83.3).01/01/2026 – 30/06/2026

Southport & Ormskirk	Whiston & St Helens
0	0

Q5

In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments:

- **CAR-T Therapy (E.g. Axicabtagene ciloleucel)**
- **Stem cell transplant or bone marrow transplant (autologous or allogeneic)**
- **Any other treatment**

(ICD 10 – C83.3) 01/01/2026 – 30/06/2026

Treatment	Southport & Ormskirk	Whiston & St Helens
CAR-T Therapy (E.g. Axicabtagene ciloleucel)	0	0
Stem cell transplant or bone marrow transplant (autologous or allogeneic)	0	0
Any other treatment	<5	<5